🇺🇸 FDA
Patent

US 8119769

Complement depletion using recombinant human C-3 derivatives

granted A61KA61K38/00A61P

Quick answer

US patent 8119769 (Complement depletion using recombinant human C-3 derivatives) held by PLS-Design GmbH expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PLS-Design GmbH
Grant date
Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00, A61P, A61P1/00, A61P11/06